13 completed, 11 recruiting, 5 active not recruiting, 5 unknown. 12 Phase 2, 11 Phase 3, 7 Phase 1, 3 Not applicable, 3 Phase 4.
Follow Neuromyelitis Optica Spectrum Disorder: new trials by email Literature Review of Neuromyelitis Optica Spectrum Disorder trials Research Report on Neuromyelitis Optica Spectrum Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder Anti-BAFFR CART - Neuromyelitis Optica Spectrum Disorder | Phase 1 / Phase 2 | Not yet recruiting | Tianjin Medical University General Hospital | 20 | 2026-12-01 | 2026-10-16 |
| Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy UPLIZNA - Neuromyelitis Optica Spectrum Disorder, Pregnancy Related | Recruiting | Amgen | 60 | 2026-10-15 | 2026-08-31 | |
| Early Prediction of Outcomes Following Optic Neuritis: Development and Acceptability of a Prognostic Tool No Intervention: Observational Cohort - Optic Neuritis, Multiple Sclerosis | Not yet recruiting | King's College London | 180 | 2026-09-01 | 2026-07-15 | |
| Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD) Ravulizumab - NMOSD, Neuromyelitis Optica Spectrum Disorder | Phase 3 | Recruiting | Alexion Pharmaceuticals, Inc. | 19 | 2026-07-20 | 2026-09-11 |
| A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy CD20/BCMA-directed CAR-T cells Autologous 2nd generation - Multiple Sclerosis (MS), Myasthenia Gravis (MG) | Phase 1 | Not yet recruiting | The Affiliated Hospital of Qingdao University | 18 | 2026-07-01 | 2026-06-30 |
| A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) Satralizumab - Neuromyelitis Optica Spectrum Disorder, NMOSD | Phase 3 | Recruiting | Hoffmann-La Roche | 8 | 2026-05-06 | 2026-10-01 |
| Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder MR-C-014 - Neuromyelitis Optica Spectrum Disorder | Not applicable | Enrolling by invitation | MedRhythms, Inc. | 30 | 2024-11-12 | 2026-07-06 |
| Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD) Calculus bovis sativus (CBS) - Idiopathic Inflammatory Demyelinating Disease, Multiple Sclerosis | Not applicable | Recruiting | Tongji Hospital | 250 | 2024-08-08 | 2024-09-20 |
| Biomarkers in Autoimmune Disease of Nervous System biomaker levels - Autoimmune Diseases of the Nervous System, Neuromyelitis Optica Spectrum Disorder | Recruiting | Tongji Hospital | 50000 | 2024-07-31 | 2026-07-29 | |
| Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders Inebilizumab, oral immunosuppressant - Neuromyelitis Optica Spectrum Disorder | Unknown | Xuanwu Hospital, Beijing | 50 | 2024-07-09 | 2024-09-19 | |
| FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack Efgartigimod Alfa Injection, High-dose intravenous methylprednisolone - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 2 | Unknown | Tianjin Medical University General Hospital | 63 | 2024-07-05 | 2024-07-11 |
| Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) Blood tests, Inebilizumab - Neuromyelitis Optica Spectrum Disorder | Phase 4 | Active not recruiting | Amgen | 32 | 2024-04-02 | 2025-11-21 |
| Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies Neuromyelitis Optica Spectrum Disorder, NMOSD | Recruiting | Alexion Pharmaceuticals, Inc. | 200 | 2023-08-30 | 2026-10-13 | |
| Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder Inebilizumab - Neuromyelitis Optica Spectrum Disorder | Phase 2 | Recruiting | Amgen | 15 | 2023-07-03 | 2025-12-05 |
| Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) Mitoxantrone Hydrochloride Liposome Injection - Neuromyelitis Optica Spectrum Disorder | Phase 2 | Completed | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 46 | 2022-11-28 | 2024-08-07 |
| Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders Daratumumab, Placebo - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 2 / Phase 3 | Active not recruiting | Tianjin Medical University General Hospital | 135 | 2022-11-01 | 2025-03-30 |
| Effects of Ofatumumab Treatment on Immune Cells and Meningeal Lymphatic Drainage in Patients With Demyelinating Diseases Ofatumumab - Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder | Unknown | Tianjin Medical University General Hospital | 34 | 2022-10-15 | 2022-10-20 | |
| A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) MIL62, Placebo - Neuromyelitis Optica Spectrum Disorder | Phase 3 | Active not recruiting | Beijing Mabworks Biotech Co., Ltd. | 102 | 2022-08-18 | 2025-09-25 |
| A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention Satralizumab 120 mg - Neuromyelitis Optica Spectrum Disorder, NMOSD | Phase 4 | Terminated | Hoffmann-La Roche | 4 | 2022-08-02 | 2025-01-22 |
| Ofatumumab in AQP4-IgG Seropositive NMOSD Ofatumumab - Neuromyelitis Optica Spectrum Disorder | Phase 1 / Phase 2 | Recruiting | Tang-Du Hospital | 5 | 2022-06-28 | 2026-01-30 |
Showing 20 of 43. Sign in to see all of them.
Neuromyelitis Optica (43) · Multiple Sclerosis (9) · Myelitis, Transverse (8) · Optic Neuritis (8) · Demyelinating Diseases (5) · Recurrence (4) · Autoimmune Diseases of the Nervous System (3) · Encephalomyelitis, Acute Disseminated (3) · Myasthenia Gravis (3) · Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (3) · Autoimmune Diseases (2) · Myositis (2) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (2) · Anti-N-Methyl-D-Aspartate Receptor Encephalitis (1) · Breast Feeding (1)
Cranial Nerve Diseases (43) · Demyelinating Autoimmune Diseases, CNS (43) · Eye Diseases (43) · Immune System Diseases (43) · Nervous System Diseases (43) · Optic Nerve Diseases (43) · Autoimmune Diseases (41) · Autoimmune Diseases of the Nervous System (40) · Demyelinating Diseases (38) · Myelitis, Transverse (35) · Optic Neuritis (35) · Neoplasms (11) · Neoplasms by Site (11) · Nervous System Neoplasms (11) · Neurodegenerative Diseases (11)
eculizumab (3) · inebilizumab (3) · ravulizumab (3) · satralizumab (3) · Adrenal Cortex Hormones (2) · Azathioprine (2) · Rituximab (2) · ofatumumab (2) · Bevacizumab (1) · Bortezomib (1) · Cyclophosphamide (1) · Hematologic Tests (1) · Immunoglobulins, Intravenous (1) · Immunosuppressive Agents (1) · LFB-R603 (1)
Alexion Pharmaceuticals, Inc. (7) · Tianjin Medical University General Hospital (5) · Amgen (3) · Hoffmann-La Roche (3) · Tongji Hospital (3) · Johns Hopkins University (2) · Tang-Du Hospital (2) · Abide Therapeutics (1) · Assiut University (1) · Beijing Mabworks Biotech Co., Ltd. (1) · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (1) · Chinese PLA General Hospital (1) · CorEvitas (1) · Hospices Civils de Lyon (1) · Isfahan University of Medical Sciences (1)
United States (18) · China (17) · South Korea (9) · Italy (8) · Japan (8) · United Kingdom (8) · Canada (7) · Spain (7) · Germany (6) · Argentina (5) · France (5) · Poland (5) · Turkey (Türkiye) (5) · Australia (3) · Croatia (3)
Michael Levy, MD, PhD (2) · Wei Wang, MD (2) · Anu Jacob, MD DM FRCP (1) · Benjamin M Greenberg, MD (1) · Chao Zhang, M.D., Ph.D. (1) · Dai-shi Tian, MD (1) · Dean M Wingerchuk, MD (1) · Eric Klawiter, MD (1) · Hongzeng Li (1) · Huanfen Zhou, PhD (1) · Jacqueline Palace, FRCP DM (1) · Jun Guo, M.D. (1) · Junwei Hao, MD (1)
PMID 33676197, PMID 34498507, PMID 23568718, PMID 28831548, PMID 30679041, PMID 31050279, PMID 33310418, PMID 34803867, PMID 37479377, PMID 37658205, PMID 38356884, PMID 40164501, PMID 40425008, PMID 40743487, PMID 41101309, PMID 41782198, PMID 42177718, PMID 42441931, PMID 42575985
2019 (4), 2023 (2)